From January 1, 2024 to March 31, 2024, the company has repurchased 2,966,000 shares, representing 0.2% for CNY 38.41 million. With this, the company has completed the repurchase of 7,023,100 shares, representing 0.48% for CNY 99.99 million under the buyback announced on November 14, 2023.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
17.34 CNY | -0.63% | -0.74% | +18.20% |
13/05 | Huahai Pharmaceutical's Unit Gets Nod to Register Atomoxetine Hydrochloride Oral Solution | MT |
02/05 | Huahai Pharmaceutical's Q1 Profit Jumps 57%, Income Up 21% | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.20% | 3.54B | |
+29.98% | 684B | |
+30.34% | 568B | |
-3.52% | 361B | |
+18.59% | 329B | |
+4.07% | 284B | |
+16.21% | 240B | |
+9.66% | 208B | |
-6.83% | 200B | |
+7.09% | 166B |
- Stock Market
- Equities
- 600521 Stock
- News Zhejiang Huahai Pharmaceutical Co., Ltd.
- Tranche Update on Zhejiang Huahai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 14, 2023.